Guggenheim Reaffirms “Buy” Rating for Verve Therapeutics (NASDAQ:VERV)
Guggenheim restated their buy rating on shares of Verve Therapeutics (NASDAQ:VERV – Free Report) in a report published on Tuesday,Benzinga reports. A number of other research analysts have also recently issued reports on the stock. William Blair reissued an “outperform” rating on shares of Verve Therapeutics in a research note on Friday, February 21st. HC […]
Guggenheim restated their buy rating on shares of Verve Therapeutics (NASDAQ:VERV – Free Report) in a report published on Tuesday,Benzinga reports. A number of other research analysts have also recently issued reports on the stock. William Blair reissued an “outperform” rating on shares of Verve Therapeutics in a research note on Friday, February 21st. HC […]
